Gabather AB (GABA) AI Stock Analysis

• Market Cap: kr24.29M
• Dividend Yield: N/A
• Average Volume (3M): 488.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.65
• Revenue Growth: N/A
• EPS Growth: 72.30%
• Country: SE
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 491,634,160
• 10 Day Avg. Volume: 541,248
• 30 Day Avg. Volume: 488,507
• PEG Ratio: 0.01
• Price to Book (P/B): -6.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: kr0.05 ▲(53.33% Upside)
• Action: Reiterated Date: 03/20/26
• Date: Action: Reiterated 03/20/26

The score is primarily weighed down by weak financial performance (no revenue, negative equity, and ongoing cash burn despite some loss improvement). Technicals add support as the stock trades above major moving averages with mildly positive momentum, but valuation remains unattractive/unclear due to negative earnings and no dividend information.

Positive Factors

No debt on balance sheet

Reported zero total debt materially lowers leverage and bankruptcy risk, preserving financing flexibility for R&D or partnerships. Over a multi‑month horizon this improves the company’s ability to secure non‑debt funding or negotiate better lending terms when needed.

Narrowing net loss trend

Consistent reduction in net losses suggests improving cost control or program efficiency. If sustained, this trend lengthens runway and lowers near‑term dilution pressure, indicating management has made structural adjustments that improve operational resilience.

Demonstrated ability to cut cash burn

A marked drop in operating cash outflows shows management can materially reduce spending when required, enhancing short‑term runway and strategic optionality. This capability, if repeated, supports longer‑term program funding without immediate dilution.

Negative Factors

Pre‑revenue business model

Absence of operating revenue means value and sustainability hinge entirely on successful clinical progress, regulatory approvals, or partner deals. This structural reliance increases execution and financing risk and keeps cash needs elevated over months ahead.

Negative shareholders' equity

Negative equity indicates accumulated losses have eroded the capital base, weakening balance‑sheet resilience. This reduces capacity to absorb shocks, can impair financing terms, and raises the likelihood of dilutive equity raises or constrained partner negotiations.

Persistent and volatile cash burn

Ongoing negative and volatile cash flows create continuous reliance on external financing. That structural funding dependence increases dilution risk, can delay programs if capital markets tighten, and limits strategic flexibility over the next several months.

Gabather AB Business Overview & Revenue Model

Company Description

Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was incorporated in 2014 and is based in Södertälje Sweden.

How the Company Makes Money

null

Gabather AB Financial Statement Overview

Summary

Pre-revenue profile with persistent losses and ongoing cash burn. Net loss has narrowed versus earlier years, and the company has no debt, but negative equity and volatile operating/free cash flow indicate weak financial resilience and continued reliance on external financing.

Income Statement

The company reports no revenue across the available annual periods, indicating it remains pre-commercial. Losses are persistent, but the trend has improved versus earlier years: net loss narrowed from about -15.0M (2020) to -7.8M (2024) and -4.7M (2025). Even with the smaller loss in 2025, profitability is still materially negative and the lack of revenue makes the earnings profile highly dependent on funding rather than operating momentum.

Balance Sheet

Total debt is reported as zero, which reduces financial leverage risk. However, equity has deteriorated sharply and turned negative (about -0.9M in 2025 after -4.2M in 2024), which is a key balance-sheet weakness and suggests accumulated losses have eroded the capital base. Total assets also declined meaningfully from 7.4M (2023) to 1.8M (2024) before rebounding to 3.8M (2025), indicating volatility in the asset base and limited balance-sheet resilience.

Cash Flow

Operating cash flow and free cash flow are consistently negative, reflecting ongoing cash burn. Cash burn improved versus 2023 (operating cash flow about -11.6M in 2023 to -3.3M in 2024), but worsened again in 2025 (about -7.2M). With no revenue and continued negative free cash flow, the business likely relies on external financing to sustain operations, and the year-to-year swing in cash usage increases funding risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-4.53M	0.00	37.00K	-8.55M	-16.99M
Net Income	-4.65M	-7.75M	-9.44M	-8.54M	-17.00M
Balance Sheet
Total Assets	3.83M	1.83M	7.36M	6.75M	15.39M
Cash, Cash Equivalents and Short-Term Investments	3.14M	878.00K	1.11M	6.27M	14.85M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	4.69M	6.01M	6.88M	3.31M	4.43M
Stockholders Equity	-863.00K	-4.17M	486.00K	3.44M	10.96M
Cash Flow
Free Cash Flow	-7.22M	-3.33M	-11.64M	-9.60M	-16.12M
Operating Cash Flow	-7.22M	-3.33M	-11.64M	-9.60M	-16.12M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	9.49M	3.09M	6.49M	1.02M	46.00K

Gabather AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GABA, the sentiment is Positive. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.03, and below the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 54.50 is Neutral, neither overbought nor oversold. The STOCH value of 33.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:GABA.

Gabather AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NANEXA	56 Neutral	kr641.88M	-60.92	-48.65%	―	-60.33%	58.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GABA	47 Neutral	kr24.29M	-1.13	―	―	―	72.30%
ALZCUR	44 Neutral	kr194.78M	-4.22	-90.66%	―	―	15.74%
VIVE	43 Neutral	kr89.46M	-2.00	-24.83%	―	―	―
KLAR	42 Neutral	kr193.83M	-3.17	-530.21%	―	―	17.42%
ERMA	40 Underperform	kr27.30M	-1.77	―	―	―	―